Vernalis is a UK-based specialty bio-pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.
Product Focus
Apokyn® (apomorphine hydrochloride injection) is the only acute, intermittent therapy available in the U.S. for the treatment of immobilising “off” episodes associated with advanced Parkinson’s disease.
Frova® is a selective 5-HT1B/1D receptor agonist approved in the United States and Europe as an acute oral treatment for migraine headache.
Distinctive Characteristics
- Lowest headache recurrence rates in the triptan class
- Long half-life of 26 hours
.
Product Pipeline
To find out more details of the conditions we are seeking to treat: view our product pipeline.